Abstract. Adoptive Cell Transfer therapy of cancer is currently in full development and mathematical modeling is playing a critical role in this area. We study a stochastic model developed by Baar et al., 2015 for modeling immunotherapy against melanoma skin cancer.
. Main cell interactions in ACT Therapy: The killing of a differentiated melanoma cell by a T cell produces more T cells and cytokines T N Fα (first line); the switch between differentiated and dedifferentiated melanoma cells is reversible (second line); a T cell cannot kill a dedifferentiated melanoma cell (third line) [4, 21] .
the stimulation of T cells which recognize one specific type of melanoma tumor cells (differentiated melanoma cells) through special markers on their surface. The stimulated T cells are then able to kill these differentiated melanoma cells. The authors of [21] showed that during the inflammation induced by the therapy, pro-inflammatory cytokines called T N F α (Tumor Necrosis Factor) which are released in the body enhance a cell-type switch: the markers on the differentiated cancer cells disappear. They become dedifferentiated, and cannot get killed by T cells anymore. The resulting tumor tissue consists of both differentiated and dedifferentiated melanoma cells. Note that the switch is reversible (i.e, the melanoma cells can recover their initial type) and it does not require cell division or mutation. Figure 1 illustrates the described interactions between cells during the treatment: the production of more T cells (plus the production of cytokines T N F α ) when a T cell kills a differentiated melanoma cell; the cell-type switch between differentiated and dedifferentiated melanoma cells; and the fact that a T cell cannot kill a dedifferentiated melanoma cell.
In immunotherapy (as in other treatments against cancer) the relapse is one of the main problems to manage. The authors of [4, 21] describe two kinds of relapse in the ACT therapy. First, T cells only recognize the differentiated cancer cells through special markers and not the dedifferentiated cancer cells that do not possess these markers on their surface. Thus, T cells are not capable of killing these dedifferentiated cells, which growth implies a relapse as shown on Figure 2 . Second, T cells can become exhausted (their quantity falls down below a certain threshold) and they no longer kill differentiated cancer cells thus causing a relapse. This problem was addressed in [21] by T cells restimulation, which only lead to a delay in the occurrence of the relapse.
In these recent years, a lot of potentials have been seen in immunotherapy treatments, including the possibility of higher effectiveness [31] with lower side effects. It should be noted that, while immunotherapy techniques have shown very few and less serious side effects, long-term effects have not yet been studied in clinical trials. These promising new treatments are thus still to be understood. An alternative to long clinical trials which are costly is to study long term effects (treatment failure and relapse) through the development of mathematical models. Numerous mathematical models have been proposed for the cancer study: deterministic models mainly based on partial differential equations Figure 2 . Relapse with dedifferentiated melanoma cells (in red) not killed by T cells [21] .
The ACT therapy induces an inflammation and the melanoma cells react to this environmental change by switching their type (special markers on the differentiated melanoma cell surface disappear). The T cells are not capable of killing switched differentiated melanoma cells, and a relapse is observed: the tumor grows again. The switch thus allows tumors to be resistant to the therapy.
or ordinary differential equations [5, 25, 33, 34] , stochastic models like individual-based models or diffusion models [4, 8, 26] and often a combination of both [3, 28] .
The purpose of the present paper is to study the relapse and failure of skin cancer immunotherapy in mice using mathematical models and real biological data. First, we estimate the parameters of the mathematical model developed by Baal et al. [4] which is adapted to the problem. Then, with the estimated parameters, we study the treatment relapse and failure focusing on T cell exhaustion and propose to optimize the treatment plan.
The stochastic individual-based model recently proposed by [4] aims to describe the ACT therapy presented in the article [21] . Its main features are: modeling the reproduction and the death of cancer cells and active T cells with birth and death processes [19] (the stimulation of T cells is modeled as birth of active T cells and their exhaustion as death of active T cells); modeling the switch between the two types of melanoma cancer cells; taking into account the interactions between cancer cells and T cells in a predator-prey framework [6, 10] . The different events (reproduction, death and switch events) occur at exponential random times in the model calibrated by rate parameters. The large population limit (large number of cells) of the stochastic model is a deterministic differential system [4] .
The authors of [4] have provided a set of biologically relevant parameters for which the stochastic system exhibits exhaustion of the T cells with high probability. However, these parameters have been calibrated numerically [4] but not estimated from real data. Our first objective is thus to estimate these parameters from the biological data given in [21] . The direct estimation of parameters in the stochastic model is problematic due to its likelihood function defined as a multiple integral over a high dimension event space. To the best of our knowledge, there exists no statistical method to estimate the parameters of such models. As an approximation, we consider the likelihood of the deterministic differential system. We therefore estimate the parameters of the model through its deterministic limit using experimental data of tumor growth in mice provided by [21] . The database is composed of tumor size measurements along time in three groups of mice: a control group showing the tumor growth in absence of treatment, a group treated with ACT therapy and a group treated with ACT therapy and restimulation, i.e. reinjection of T cells.
This last group allows to study the effect of the restimulation on the relapse. We analyze these longitudinal data simultaneously with a Nonlinear Mixed Effects Model (NLMEM) [27] that takes into account the variability between the mice (population and individual parameters are estimated). Indeed, longitudinal data are very common in cancer studies. Mixed effects models [27] are well adapted to such data and are often involved in parameter estimation in cancer models [7, 12, 17] . The Stochastic Approximation Expectation Maximization (SAEM) algorithm [11] is used to estimate the parameters of the NLMEM.
Once the parameters have been estimated, T cell exhaustion is studied by heading back to the stochastic model. Indeed, complete exhaustion is a purely stochastic phenomenon which is not modeled by the deterministic system. As T cell exhaustion can be a rare event, we estimate it using a splitting Monte Carlo method adapted to rare event probability estimation [18, 24] . We observe that, in the range of parameters estimated from real data, the exhaustion probability can be non negligible, which confirms a conjecture in [4] .
As this kind of relapse can be delayed by restimulation of T cells, our second objective is to optimize the ACT protocol in this sense. We propose a treatment optimization plan based on the computation of optimal treatment doses and restimulation times by minimizing the T cell exhaustion probability at different stages of the disease evolution.
The paper is organized as follows. In section 2 we present the experimental data used for parameter estimation. In section 3, the stochastic model and its deterministic limit are described. In section 4, we first present the statistical tools involved in the parameter estimation of the deterministic system, as well as the estimated parameter values. Second, we describe the T cell exhaustion probability estimation procedure and estimate the exhaustion probability as a function of the T cells death rate. In section 5, we perform the ACT treatment optimization and present the related results.
Experimental data on Adoptive Cell Transfer therapy
We first describe the experimental setup of [21] , from which we use the data. Initially, a small quantity M 0 of melanoma cells (around 10 4 ) is placed inside each mouse of the experiment. Thus, the initial size of the tumor is very small. Mice are then split into 3 groups: untreated mice playing the role of a control group (denoted CTRL) and treated mice composed of two subgroups: mice treated once with ACT therapy (denoted ACT) and mice treated twice with ACT therapy (denoted ACT+Re). After 70 days (at time t a = 70), mice of ACT and ACT+Re groups receive a dose d 70 of a T cell stimulant activating 2000 T cells and conferring them the ability to kill differentiated melanoma cells. Mice in ACT+Re group receive an additional dose d Re of the T-cell stimulant at restimulation time t Re = 160 activating again 2000 T cells.
During the experiment, the tumor development is measured by palpation when the tumor is small and digital photography when the tumor is larger. The tumor size is measured weekly using a vernier caliper and recorded as mean diameter [21] . Longitudinal data for 19 mice are composed of 5 mice of CTRL group (with an average number of 10 observations per mouse); 7 mice of ACT group (with an average number of 26 observations); and 7 mice of ACT+Re group (with an average number of 33 observations). The measure of tumor size, if it is smaller than 2 mm, is very inaccurate due to the difficulties of palpation. Thus, these values are left censored. For tumor size between 2 mm and 3 mm, the inaccuracy is still important on the measures, about 1 mm. These values are interval censored in [2, 3] . Mice with tumor size exceeding 10 mm or showing signs of illness are killed. Thus measurements exceeding 10 mm are considered as right censored. The other tumor sizes between 3 mm and 10 mm are considered as measured correctly with a measurement accuracy around 0.5 mm. Figure 3 represents the evolution of the tumor diameter along time for all the mice. The three censorships are illustrated by aligned horizontal points. Excluding the observations at t 0 = 0, mice in CTRL group are not concerned by left-censorship. Observe that the three groups of mice are distinguished by the rapidity in the evolution of their tumor size: tumor size of CTRL group (in blue) reaches quickly 10 mm around the 100th day, tumor size of ACT group (in red) reaches 10 mm between the 240 and 300 days and finally tumor size of ACT+Re group (in green) reaches 10 mm beyond the 300th day. Treatment and retreatment times are indicated by (black) vertical dotted lines. We distinguish two phases in the ACT therapy (for treated mice): the growth phase (before t a = 70) and the treatment phase (after t a = 70). Note that the mice in CTRL group have only the tumor growth phase.
3. Modeling tumor growth under treatment 3.1. A stochastic model with four cell types. The stochastic model proposed in [4] for tumor growth under ACT therapy consists in a four-dimensional continuous time Markov process Figure 4 . Dynamics of the stochastic process: natural and therapy induced birth/death of cells, T cell exhaustion, switches between the two types of melanoma cells and rates associated to these events. M for differentiated melanoma cells; D for dedifferentiated melanoma cells; T for T cells; A for cytokines T N Fα. † symbolizes the death of cancer cells and cytokines; E symbolizes the exhaustion of T cells. The orientation of the arrow indicates the sense of the evolution of the population (an arrow with the initial and end points on the same population indicates a reproduction in this population). The values above the arrows represent the rates [4] .
with M (t) the population of differentiated melanoma cells, D(t) the population of dedifferentiated melanoma cells, T (t) the population of active T cells, and A(t) the population of cytokines T N F α at time t.
The growth phase of the disease (t < 70) is characterized by the reproduction and death of melanoma cancer cells plus the natural switch between these two cancer cell populations. At this stage, there are no active T cells nor cytokines T N F α (T (t), A(t)) = (0, 0). The evolution of M (t) and D(t) is modeled by birth and death processes [19] including additional terms modeling the switches between the two cancer cell populations. . The system models the evolution of differentiated melanoma cells M (t) (preys) in the presence of active T cells T (t) (predators) as a predator-prey framework. An additional natural exhaustion of active T cells is modeled by a simple death process. A deterministic production of cytokines A(t) occurs at each T cell reproduction event while the death of cytokines is modeled by a death process. An additional switch from differentiated to dedifferentiated melanoma cell due to the presence of cytokines is also modeled. The ACT group is modeled by the growth phase and this first treatment phase. × b T represents the production rate of cytokines induced by the therapy and s A is associated to the additional switching from differentiated to dedifferentiated melanoma cells induced by cytokines. We estimate the above described parameters as well as the initial quantity M 0 of differentiated melanoma cells which value is not fixed from one mouse to another.
3.2.
Deterministic limit of the stochastic model. The stochastic model converges in the limit of large population of cells to the solution of the following deterministic differential system:
with initial condition (n M 0 , n D 0 , n T 0 , n A 0 ). A precise statement of this fact is given in [4] . Quantity n X (t) ∈ R (with X = M, D, T or A) represents the quantity of X at time t anḋ n X represents the variation of this quantity along time. Note that we work in this paper on a simplified version of the initial model [4] . Some competition terms were removed as they cannot be estimated from the data. Indeed, mice are killed before the tumor size (number of cancer cells) reaches the (non trivial) fixed point regulated by the competition terms. To avoid the problem of identifiability, new parameters are introduced:
keeping in mind that only the difference between birth and death rates of melanoma cells can be estimated from the data.
The different phases of the therapy are similar to the ones of the stochastic model. During the growth phase (t < 70), only populations of cancer cells n M (t) and n D (t) evolve (n T (t), n A (t)) = (0, 0). All parameters associated with the treatment are then equal to zero. At time t = 70, the quantity of active T cells is set as n T (70) = d 70 . The four populations of cells (n M (t), n D (t), n T (t), n A (t)) evolve. The model (3.1) corresponds to the dynamics of the ACT group. For ACT+Re group, an additional quantity of active T cells is added in the system at time t Re = 160 (n T (160) = n T (t) + d Re ). 4 . Estimation of the division-, death-and switch-rates based on the experimental data 4.1. Mixed Effects Model for tumor growth under treatment. The parameters are estimated by analyzing the three groups simultaneously. We use a Nonlinear Mixed Effects regression Model (NLMEM) to take into account the inter-mice variability [27] . Parameter estimation with NLMEMs is difficult since the likelihood function does not have an explicit form. When the regression function of the NLMEM is the stochastic model, the high dimension of the event space prevents to compute the likelihood. Thus, we choose to perform the parameter estimation based on the maximization of the likelihood function of the deterministic model (3.1). Let us define y i = (y i1 , . . . , y in i ) where y ij is the (noisy) measurement of the tumor diameter value for mouse i at time t ij , i = 1, . . . , N , j = 1, . . . , n i , and set y = (y 1 , . . . , y N ). The NLMEM is defined by:
where denotes component-wise multiplication and
η i is a vector of random effects independent of i ; ψ i represents the vector of individual regression parameters;
is describing the tumor diameter (up to some constant), with n M and n D being solution of the nonlinear system (3.1); σ 2 is the residual variance; I n i the identity matrix of size n i ; Ω the variance matrix of the random effects quantifying variability between mice. We note θ = (µ, Ω, σ 2 ) the parameters to be estimated. A biological constraint states that the natural switch rate from a dedifferentiated melanoma cell to a differentiated melanoma cell (s DM ) is greater than the rate in the other direction (s M D ) [21] . This constraint is taken into account by estimating s DMp such that
4.2. Parameter estimation using SAEM algorithm. The SAEM-MCMC algorithm which combines the Stochastic Approximation Expectation Maximization algorithm [11] with a Markov chain Monte Carlo procedure adapted to censored data [20, 32] , implemented under the software MONOLIX [23] , is used to estimate the model parameters. (93) 3.23 (25) σ 0.44 (6) 0.03 Table 1 . Estimated parameters for the final model: population mean ρ pop and inter-mice standard deviation ω ρ for the log-normal distribution
estimation × 100 (in brackets). ω ρ = 0 for parameters without random effect and (-) means that the standard error is not estimated (the parameter is fixed).
We first proceed to model selection through likelihood ratio tests. We start with the model having random effects on all parameters. Likelihood ratio tests lead to the model given by {η
Then, effect of the categorical covariate group denoted by G is tested on the fixed ef-
ACT group is taken as reference group, G = {ACT*, ACT+Re, CTRL}. Tests results showed that none of the parameters is function of the covariate group G, i.e., the model captures the differences between groups well enough without the help of an additional covariate. Thus, we take as final model the one after likelihood ratio tests. We estimate the Fisher Information Matrix (F.I.M.) and the associated standard errors for this model. In order to simplify the estimation of the F.I.M (very difficult numerically here), we fix the mean of population parameters d A and s DMp to their estimated values. Table 1 11, 12 ). Indeed, the tumor growth phase is well fitted for CTRL mice as well as for treated mice (before the beginning of therapy). Treatment effect in tumor size dynamics from the 70th day is also well highlighted in both ACT and ACT+Re groups. Furthermore, the restimulation effect is well marked in the tumor size dynamics for ACT+Re mice. Another positive point of the model is that no additional covariate 
4.4.
Biological relevance of the switching rate parameter. From a biological point of view, an important fact is that the switching rate from differentiated melanoma cells to dedifferentiated ones s A is expected to be higher than the killing rate of differentiated cells by T cells t T [1] . This is corroborated by the estimated parameters (s A > t T , see Tables  1 ). Note that the calibration of model parameters in [4] led to t T much greater than s A . Thus, by confirming this relation expected by biologists, the parameters estimated in this paper lead us in a more realistic model.
Relapse due to T cell exhaustion
T cell exhaustion is a cause of relapse due which was highlighted in [4] . It is defined by the stochastic event {T (t) ≤ S, t ≤ t F } where S is the exhaustion threshold and t ≤ t F a condition for exhaustion to occur in a finite time. The complete T cell exhaustion (S = 0) is a phenomenon which can only occur in the stochastic system: when the T cell population is low enough, the stochastic fluctuations can drive it to extinction, whereas the T cell population can never vanish in the deterministic limiting system. This follows from the analyticity of the solutions to (3.1), given that T (70) > 0.
5.1. Very small T cell exhaustion probability for population parameters. We want to estimate the exhaustion probability p = P(T (t) ≤ S, t ≤ t F ). Let u = 1 T (t)≤S . Using the intuitive Monte Carlo method, T cell exhaustion probability is estimated bŷ p = N T k=1 u k /N T with N T the total number of simulations. However, depending on the values of the model parameters, the exhaustion threshold S may be difficult to reach leading sometimes to very small probabilities. Monte Carlo method thus requires a large number N T of simulations when the probability p is very small. This method is therefore not suitable for estimating the probability of T cell exhaustion because the variance will diverge when the probability tends to zero for a reasonable value of N T [24] . To reduce the variance for very small probabilities estimation, an alternative is the Importance Splitting (IS) algorithm designed for rare event probability estimation [9, 18, 24] . Indeed, IS gradually calculates the probability of reaching the threshold S (the rare event) through the calculation of the probability of reaching intermediate thresholds easier to reach than S. Thus, the probability P(T (t) ≤ S, t ≤ t F ) is calculated according to the splitting principle by
The S k (k < m) are the intermediate thresholds and S m = S the exhaustion threshold. The IS algorithm consists at each iteration k in the simulation of N T trajectories of the process T t and the estimation (by Monte Carlo) of the intermediate probability p k by considering the number N S k of trajectories which reach the intermediate threshold
To pass from iteration k to iteration k + 1, N T trajectories are sampled from the N S k trajectories having reached the threshold S k (by allowing replacement in the sampling) and run the N T new trajectories in order to reach the next threshold S k+1 . In our setting, we consider that there is T cell exhaustion at time t when the quantity of T cells at t reaches S 5 = 0. Then, we define four other intermediate thresholds
, and S 4 = 2 × 10 −5 (0.1% of T (70)). We set N T to 1000.
First of all, the T cell exhaustion probability estimated by the IS algorithm is "zero" (very close to absolute zero) for both individual and population parameters in both ACT and ACT+Re groups. Figure 6 shows the dynamics of cancer cells, T cells, and cytokines for population parameters in the ACT group. For these sets of parameter values, T cells thus survive and continue to kill differentiated cells (whose number does not explode). However, the therapy enhanced the production of dedifferentiated melanoma cells (not killed by T cells) leading to a large increase in their number. Furthermore, since the tumor is formed by the sum of differentiated and dedifferentiated melanoma cells, we observe a regrowth in tumor size (relapse). Thus, we highlight the existence of sets of biological parameters (estimated from biological data) for which a relapse due to the dedifferentiated melanoma cells occurred.
5.2.
Evolution of T cell exhaustion probability with respect to therapy parameters. Some of the estimated parameters have a random effect. We study the T cell exhaustion by naturally taking into account their distribution. We start with the death rate of T cells d T which is one of the parameters which is the most relevant for the therapy. We thus estimate the T cell exhaustion probability as a function of
) when the other parameters are fixed to their estimated population values (still in ACT group). The T cell exhaustion probability increases with d T , and even reaches non negligible values ( Figure 7) . Furthermore, when the T cell exhaustion occurred, we observe an explosion of the number of differentiated melanoma cells (for a relatively small dedifferentiated cell population) leading to a relapse. This corroborates the hypothesis in [4] which asserts that there exist biological parameters for which the probability of disease relapse due to T cell exhaustion is non negligible.
Note that the computation of T cell exhaustion probability (for one given set of parameter values) requires N T = 1000 simulations of the stochastic model for each of the m = 5 thresholds of IS algorithm. Furthermore, each trajectory (among the four composing one simulation) can contain up to 100 millions of stochastic events. This stochastic approach is therefore very expensive in computing time. For example, the average time to calculate the exhaustion probability for hours (using 3 cores, with 7GB of memory per core). However, this stochastic approach allows us to highlight a link between the probability of T cell exhaustion and the depth of the corresponding T cell deterministic minimum (Figure 7) . Indeed, we note that the lower the deterministic minimum the greater the probability of T cell exhaustion. We thus exploit this relation to cheaper study the effect of the other parameters having a random effect on the T cell exhaustion phenomenon. Thus, Figure 9 shows the evolution of the depth of the T cell deterministic minimum according to these parameters.
Figures 7 and 9 allow us to get a first idea of how the evolution of the deterministic minimum (indirectly the probability of T cell exhaustion) is affected by a parameter with random effect (the others parameters being fixed to their population mean). We observe that the minimum becomes deeper and deeper when the parameters like d T , t T and l prod A , which are strongly related to therapy, evolve. On the other hand, the minimum seems to increase when disease parameters like r M , r D and n M 0 increase. We observe similar dynamics with d A . Given these observations, we can expect that the joint variation of these parameters will lead us to interesting therapeutic scenarios.
6. Treatment optimization to minimize the probability of relapse due to T cell exhaustion 6.1. Criteria to optimize treatment doses and restimulation times. The kind of relapse we can act on without changing the medical setup is the relapse due to T cell exhaustion. We thus want to minimize the probability of T cell exhaustion, i.e. to keep the minimum of T cell trajectory as high as possible in order to avoid the stochastic fluctuations cross the exhaustion threshold S = 0. Treatment parameters to be optimized are the treatment dose d 70 , the retreatment time t Re and dose d Re . Optimization is done with the deterministic model by exploiting the link between the exhaustion probability and the depth of the T cell deterministic minimum ( Figure 7 ). Cost function (to be maximized) is defined by g = min{n T (t), t ≤ t F } (6.1) with n T (t) solution of deterministic system (3.1) and t F a fixed finite time. Note that g depends on all the model parameters through n T (t). In the following, we will optimize the therapy by maximizing g over different subsets of treatment parameters.
To take into account random effects in the optimization, we consider some specific quantiles of their distribution. To reduce the size of the problem, we focus on the Tcell related parameters d T (natural death rate of T cells), t T (therapy induced death rate of the differentiated melanoma cells) and l prod A (which, multiplied by b T , leads to the therapy induced production rate of the cytokines). We then set the value of the natural death rate d A of cytokines to its population value since it is less related to T cells compared to the three previous treatment parameters and seems to have less effect on the minimum (Figure 9 ). We also set the value of the disease parameters r M and r D to their population mean assuming that these are disease-specific parameters that are less under our control. However, we consider different quantiles of the distribution of n M 0 , a disease-related parameter. Indeed, n M 0 allows to characterize the stage of the disease and is therefore a relevant variable to present our results. In summary, we set r M , r D and d A to their population values and consider specific quantiles for d T , t T , l prod A and n M 0 . We consider two optimization procedures: the first is performed on ACT group and leads in the optimal treatment dose d Table 2 . Quantile values for parameters having random effects considered in treatment optimization. q α represents the quantile of order α%.
6.2.1. Methodology. We take into account in optimization procedure the distribution of random effects η A , and n M 0 . Among these sets of parameter values, none actually presents an increased risk of T cell exhaustion. Indeed, the smaller deterministic minimum observed among these 81 sets is around 1.4 × 10 −3 in both ACT and ACT+Re groups. This value of the deterministic minimum corresponds to a T cell exhaustion probability of zero by referring to Figure 7 . However, optimizing the treatment to keep the T cell minimum as high as possible is still beneficial since it allows to further delay the possible relapse due to T cell exhaustion. Table 3 presents in its column ACT the optimization results for criterion (6.2) (for seven sets of parameter values among the 81), and in column ACT+Re the corresponding optimal parameter values for criterion (6.3).
6.2.3.
Optimal treatment values using quantiles of order 5%, 50%, 95% of t T , d T , l prod A ,n M 0 . Using the quantiles of order 5%, 50%, 95% of t T , d T , l prod A and n M 0 , we identify among the and n M 0 leading to an increased risk of T cell exhaustion (the same sets of parameters for both ACT and ACT+Re mice). For that purpose, we set the threshold of T cell exhaustion risk at S 1 = 7 × 10 −5 , i.e., the first intermediate threshold of our IS algorithm. S 1 represents a value beyond which we can start to worry that stochastic fluctuations lead to the T cell exhaustion.
Figures 10a and 10b show optimal treatment parameters corresponding to two sets of parameter values for optimization criterion (6.2) (Figure 10a presents a risk of T cell exhaustion, Figure 10b is without an exhaustion risk). Figures 10c and 10d show the optimization results for the same two sets of parameters for criterion (6.3). Table 4 presents the optimization results for the nine sets of parameter values presenting an increased risk of exhaustion. The column ACT corresponds to optimization criterion (6.2) and column ACT+Re to criterion (6.3) .
Note that parameter values leading to an increased risk of T cell exhaustion mainly correspond to high values of parameters d T and l prod A as shown for their quantile of order 95% in Figure 10 Table 3 ). Thus, we can expect that higher ). We consider six discrete values with a regular discretization for each treatment parameter: d70, dRe ∈ {0.005, 0.012, 0.019, 0.026, 0.033, 0.040}, tRe ∈ {130, 142, 154, 166, 178, 190} (with an additional value of 0 for dRe to take into account the cases where dRe = 0).
treatment dose values would further delay the T cell exhaustion or that an earlier restimulation would reduce the risk of an early exhaustion. However, the treatment parameters are optimized over optimization intervals which take into account biological considerations as explained in Section 6.2.1. It may thus be experimentally non trivial to go beyond those intervals.
Observe that, for most rate parameters (like in Figure 27 in Appendix), the larger dose, the deeper the T cell global minimum, therefore the higher the probability of T cell exhaustion.
We also observe for some parameter values (Figure 19 or sixth lines in Table 3 ) that the optimal restimulation dose is zero: d opt Re = 0. In this cases, the treatment dose d 70 is sufficient to keep the minimum high enough.
Finally, for an important number of sets of parameter values (like in Figures 10b and  10c or in Figures 18, 23, 24 , 25 in Appendix) we find optimal parameters well located inside the optimization interval (d min < d . In these cases our results provide treatment doses and restimulation times which differ from the already tested experimental ones and which lead to a more efficient therapy.
6.3.2.
Treatment optimization is more efficient on ACT+Re mice. Optimization benefits can be evaluated by calculating the probability of T cell exhaustion using the IS algorithm. As the function g (denoting the value of the deterministic minimum of the T cell population) is related to the exhaustion probability, we compare the values of g before and after optimization.
Let Imp ACT+Re = (g . For all the optimized treatment parameters, the two improvements are positive (Imp ACT+Re ≥ 0, Imp ACT ≥ 0). Moreover, the difference Imp ACT+Re − Imp ACT is always positive with a mean value equal to 65.7 ± 4.8% for the nine sets of rate parameters presenting an increased risk of T cell exhaustion (Table 4) . Thus, the best improvements are noted in ACT+Re mice compared to ACT mice. This remark makes sense since ACT+Re mice have benefited from restimulation, which boosts the effects of optimization.
Note however that the treatment optimization only minimizes the risk of T cell exhaustion for these nine sets of parameter values. Indeed, the risk does not vanish completely (for the threshold S 1 ) as it can be seen in Table 4 (g opt is still smaller than S 1 ). Considering wider optimization intervals could improve the results provided that the new limits remain biologically reasonable. 6.3.3. The larger n M 0 , the faster the tumor growth even for higher treatment doses. It has been biologically observed [1] that when the tumor size exceeds a certain threshold at the beginning of the treatment (t = 70), the tumor control is less efficient even if more T cells are stimulated. Figure 26 
Conclusion
In cancer treatment, resistance to therapy is a major problem. Understanding the mechanism of this resistance is then crucial. The parameter estimation for the mathematical model of [4] for melanoma cancer immunotherapy using biological data from [21] was essential in achieving this goal. Indeed, the estimated parameters lead to an accurate model which is necessary for further quantitative studies. We use these parameters to simulate realistic stochastic phenomena arising in the therapy and to highlight the existence of sets of biological parameters leading to each of the types of relapses identified by the authors of [4] . Moreover, we were able to quantitatively estimate the probability of relapse due to the T cell exhaustion which allows to evaluate the quality of the treatment.
In addition, we confirmed two important conjectures from the authors of [21] . First, the experimental data [21] suggest that the switch rate s A induced by cytokines should be higher than the rate t T at which T cells kill differentiated melanoma cells. Our estimated parameters support this conjecture, while calibrated parameters in [4] led to s A < t T . We thus provide a more realistic version of the model. Second, biological observations [1] show that when the tumor size exceeds a certain threshold at the beginning of the treatment (t = 70), the tumor control is less efficient even if more T cells are stimulated. We indeed highlight the low effect of high treatment doses d 70 when the tumor size reaches a certain level at the beginning of the treatment.
With the estimated parameters, we optimize the treatment protocol using the deterministic system due to the high computational cost in the stochastic setting. We perform the optimization by plotting the value of the minimum of the T cell population as a function of treatment parameters (by considering some reasonable discretization of the parameter space). By linking the value of the minimum to the exhaustion probability of T cells, we provide optimal treatment doses and (re)stimulation time(s) which minimize the probability of relapse due to T cell exhaustion.
An alternative to the use of deterministic system would be the use of a diffusion approximation of the stochastic model. Thus, a stochastic aspect would be included in the problem while remaining reasonable in computational costs. An interesting statistical challenge, which is a work in progress, is the parameter estimation in this stochastic diffusion approximation. The difficulties are mainly due to the predator-prey part and high dimension.
In this paper, we focused on the relapse due to T cell exhaustion. However, the second source of relapse due to dedifferentiated melanoma cells must also be resolved. There are prospects to handle this problem also with modifications of the treatment protocol. One solution may be to introduce another type of T cell that can kill the dedifferentiated melanoma (see [4] for a theoretical study for a model for such a treatment protocol). Another solution is to find a way to control the switching rate s A of differentiated melanoma to dedifferentiated melanoma cells [15] . Indeed, if s A is well controlled in the therapy (and if the number of dedifferentiated cells is finally zero or low enough to cause a relapse), then the problem of complete healing of mice will come down to the control of T-cell exhaustion. Thus, our work is a useful tool for new protocols of tumor treatment.
A. Appendix
Note that the code used to simulate the stochastic dynamics has been written in C++ and ran under the software R [29] through the package Rcpp [13] . Obs. y
Observed data BLQ data Spline Figure 13 . predicted values versus observed values to assess the accuracy of the final model. The blue points represents no censored observations, the red asterisk symbols the censored observations. ), nM 0 = q 50 (nM 0 i ). Vertical line at t = 70 (in gray) indicates the beginning of therapy, the vertical line at t ≥ 70 (in red) indicates the value of g(d70).
